Journal
PHARMACOPSYCHIATRY
Volume 39, Issue -, Pages S21-S25Publisher
GEORG THIEME VERLAG KG
DOI: 10.1055/s-2006-931485
Keywords
-
Categories
Ask authors/readers for more resources
Aripiprazole is the first approved atypical antipsychotic with a mechanism of action that exerts a partial agonism with high affinity at Dopamin D-2- and Serotonin-5-HT1A-receptors as well as an antagonism at Serotonin-5-HT2A-receptors. Aripiprazole provides good clinical effectiveness and a favorable profile of safety and tolerability. The special pharmacodynamics of aripiprazole are described herein.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available